Top Stories
Prasad's CBER departure triggers genetic medicine rally as analysts predict regulatory reset for rare disease drug approvals
Vinay Prasad will leave his role as FDA CBER Director at the end of April, his second departure in under a year, following sustained criticism from the rare disease community, biotech industry, and members of Congress over a pattern of rejecting or reversing previously agreed approval pathways. STAT News reported that under Prasad's leadership, CBER rejected at least five cell and gene therapies that experts believe likely could have been approved under prior leadership, with drugmakers accusing the agency of reversing earlier agreements on trial designs. UniQure shares surged 36% on the news, with the company's AMT-130 Huntington gene therapy having become what Stifel analyst Paul Matteis called "a symbol of FDA inflexibility." Regenxbio rose 13%, Biohaven 23%, Replimune 16%, and Sarepta gained 5%. RBC Capital upgraded UniQure to Outperform and raised its price target from $11 to $35, estimating a 50% probability of eventual AMT-130 approval now that Prasad's exit could reopen regulatory discussions. Clinical Trials Arena noted that Prasad's tenure included record CBER approvals in December and lasting policy reforms — the plausible mechanism framework, two-to-one pivotal trial requirement, and Commissioner's National Priority Voucher — but that the successor appointment will determine whether the agency's approach to rare disease flexibility shifts meaningfully. Commissioner Makary said a replacement will be named before Prasad's end-of-April departure.
Vertex povetacicept achieves 52 percent proteinuria reduction in IgA nephropathy Phase 3 interim analysis, advancing dual BAFF/APRIL inhibition in rare kidney disease
Vertex announced positive Week 36 interim results from the RAINIER Phase 3 trial of povetacicept in adults with IgA nephropathy, a progressive rare kidney disease. Povetacicept, an engineered fusion protein and dual inhibitor of the BAFF and APRIL cytokines, achieved a 52.0% reduction from baseline in proteinuria (UPCR) and a statistically significant 49.8% placebo-adjusted reduction (P<0.0001). IgA nephropathy affects an estimated 200,000 people in the United States, with approximately 330,000 across the US and Europe combined. The dual BAFF/APRIL mechanism differentiates povetacicept from Novartis's complement factor B inhibitor Fabhalta ($550,000/year) and Calliditas Therapeutics' targeted-release budesonide Tarpeyo (~$170,000/year). The interim analysis supports continuation to the primary Week 104 endpoint, where sustained eGFR preservation will determine long-term renal protection. The data positions Vertex to file for accelerated approval in the US in H1 2026.
Servier acquires Day One Biopharmaceuticals for $2.5 billion, adding rare pediatric glioma therapy Ojemda to oncology pipeline
Servier entered a definitive agreement to acquire Day One Biopharmaceuticals for $2.5 billion, securing Ojemda, an FDA-approved RAF kinase inhibitor for pediatric low-grade gliomas with RAF alterations. The therapy received FDA approval in 2024 for a patient population estimated at 500-700 newly diagnosed US cases per year. MedCity News reported the deal reflects Servier's strategy to build critical mass in rare oncology through acquisitions. The transaction is expected to close mid-2026, and success will depend on Servier's ability to integrate Day One's specialized pediatric neuro-oncology expertise while realizing commercial synergies across rare cancer settings.
Pipeline Watch
UniQure shares surged 36% Monday and jumped as much as 70% in after-hours trading Friday, as BioPharma Dive reported. RBC Capital upgraded to Outperform with a price target of $35 (from $11), estimating 50% probability of AMT-130 approval. UniQure's Type B meeting with the FDA in Q2 2026 will now proceed without Prasad's direct oversight, potentially reopening negotiations on whether the Phase 1/2 data showing 75% disease slowing at 3 years can support a BLA without the demanded sham surgery-controlled Phase 3.
Spruce named Dale Hooks as CCO, bringing 21 prior product launches of experience as the company prepares for its first FDA filing in classic congenital adrenal hyperplasia, a rare endocrine disorder affecting approximately 10,000-15,000 US patients, per Fierce Pharma. Tildacerfont, a CRF1 receptor antagonist, would compete with standard-of-care glucocorticoid replacement therapy, offering a differentiated mechanism for disease control without chronic steroid side effects.
GSK secured commercial rights to linerixibat, an IBAT inhibitor under development for primary biliary cholangitis and other cholestatic liver diseases, from Alfasigma for undisclosed terms, per PharmExec. The mechanism targets bile acid reabsorption, distinct from ursodeoxycholic acid and obeticholic acid, addressing pruritus and liver fibrosis progression in a rare hepatology indication where small patient populations support premium pricing.
Competitive Landscape
At least five cell and gene therapy programs rejected or reversed under Prasad's tenure — including UniQure, Regenxbio, Capricor, Biohaven, and Replimune — may benefit from a new CBER director willing to apply the regulatory flexibility the agency has publicly promised. The successor appointment, expected before end of April, will signal whether the FDA returns to the more accommodating posture toward external controls and accelerated approval that characterized Peter Marks' tenure.
| Company | Program | FDA Action Under Prasad | Stock Move on Exit |
|---|---|---|---|
| UniQure | AMT-130 (Huntington) | Sham Ph3 Demanded | +36% |
| Regenxbio | RGX-121 (Hunter) | CRL (Feb 2026) | +13% |
| Biohaven | Troriluzole (SCA) | CRL | +23% |
| Replimune | RP1 (Melanoma) | Surprise Rejection | +16% |
| Sarepta | Elevidys (DMD) | Distribution Paused | +5% |
Vertex's dual BAFF/APRIL inhibitor povetacicept and existing approved therapies address IgA nephropathy through distinct mechanisms, creating an increasingly crowded but mechanistically diverse treatment landscape. The 52% proteinuria reduction at Week 36 compares favorably to existing options, though long-term eGFR preservation data at Week 104 will determine clinical differentiation. Vertex plans to file for accelerated approval in H1 2026.
| Company | Mechanism | Status | Annual Pricing |
|---|---|---|---|
| Vertex | Dual BAFF/APRIL Inhibitor | Phase 3 | TBD |
| Novartis | Complement Factor B (Fabhalta) | Approved (Accel.) | ~$550K |
| Novartis | ETA Antagonist (Vanrafia) | Approved (Accel.) | ~$162.5K |
| Calliditas | Targeted Budesonide (Tarpeyo) | Approved | ~$170K |
| AstraZeneca | SGLT2 Inhibitor (Farxiga) | Off-Label | <$10K |
The $2.5 billion deal adds approved Ojemda to Servier's oncology portfolio, providing immediate commercial revenue in pediatric low-grade gliomas with RAF alterations. Success depends on Servier's ability to integrate Day One's specialized neuro-oncology expertise and leverage shared KOL relationships across pediatric and adult rare cancer settings, a thesis that has limited precedent in the rare oncology M&A landscape.
Forward Looking
- The CBER successor appointment, expected before Prasad's end-of-April departure, will be the most consequential personnel decision for the rare disease and gene therapy sector this year — watch for signals on whether the new director embraces external controls and regulatory flexibility for small populations.
- UniQure's Type B meeting with FDA in Q2 2026 will test whether Prasad's departure reopens a path to AMT-130 approval based on Phase 1/2 data without the sham surgery-controlled Phase 3 requirement.
- Vertex RAINIER trial will report Week 104 primary endpoint data in late 2026, determining whether proteinuria reduction translates to sustained eGFR preservation in IgA nephropathy.
- Servier-Day One transaction closure expected mid-2026, with integration milestones and Ojemda commercial performance metrics shaping the rare pediatric oncology M&A thesis.